注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Nuvation Bio Inc是一家臨床階段的生物製藥公司。該公司致力於開發針對癌症患者的差異化和新型治療候選者。該公司正在開發六種由藥物發現和開發項目產生的全資化合物,包括NUV-422 a細胞週期蛋白依賴性激酶(CDK)抑製劑、NUV-868 a bromodomain和額外末端(BET)抑製劑、NUV-569 a Wee1抑製劑、A2A腺苷受體抑製劑項目和藥物-藥物結合物(DDC)平台。其主要候選產物NUV-422是一種選擇性的CDK 2、4和6小分子抑製劑。其第二個候選產品是NUV-868,一種BD2選擇性口服小分子BET抑製劑。其正在發展中,包括NUV-569,NUV-569是一種分化的口服小分子選擇性Wee1激酶抑製劑,Wee1激酶是脫氧核糖核酸(DNA)損傷修復的重要調節因子。其子公司包括Nuvation Holdings, LLC和RePharmation Ltd。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
David T. Hung | 63 | 2018 | Founder, President, CEO & Director |
Daniel G. Welch | 63 | 2020 | Independent Chairman of the Board |
Kim D. Blickenstaff | 72 | 2019 | Independent Director |
Robert B. Bazemore | 56 | 2020 | Independent Director |
Wassim Abida | - | 2023 | Member of Scientific Advisory Board |
Johann de Bono | - | 2023 | Member of Scientific Advisory Board |
Junyuan Wang | 51 | 2024 | CEO & Co-Founder of AnHeart Therapeutics and Director |
Kathryn E. Falberg | 63 | 2020 | Independent Director |
Mansoor Raza Mirza | 63 | 2023 | Member of Scientific Advisory Board |
Robert D. Marshal | 64 | 2024 | Independent Director |
Allyson J. Ocean | 51 | 2023 | Member of Scientific Advisory Board |
Xiangmin Cui | 56 | 2024 | Director |
William Anthony Vernon | 68 | 2019 | Independent Director |
Gordon B. Mills | - | 2023 | Member of Scientific Advisory Board |
Joyce Ann O'Shaughnessy | - | 2023 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核